

Potential role of Ultraviolet Radiation therapy in ameliorating the pathogenesis of Relapsing Remitting Multiple Sclerosis

THESIS

**Submitted for partial fulfillment of M.Sc. Degree in
Neuropsychiatry**

By

Wael Mahmoud Ezzat Ibrahim

Demonstrator of Neurology
Kasr Alainy Faculty of Medicine – Cairo University

Supervised by

Prof. Shereen Fathi Sheir

Professor of Neurology – Cairo University

Ass.Prof. Fatma Mohamed Taha

Ass.Professor of Biochemistry – Cairo University

Dr. Abdelazim Mohammed Reda

Lecturer of Neurology – Cairo University

Faculty of medicine
Cairo University
2014

الدور العلاجي المحتمل للأشعة فوق البنفسجية لتحسين التسبب في التصلب المتناثر ذو الطبيعة الإنتكاسية

رسالة مقدمه من
الطبيب / وائل محمود عزت إبراهيم
معيد الامراض العصبية
(جامعة القاهرة)

توطئة للحصول على درجة الماجستير
فى الأمراض العصبية والنفسية

تحت إشراف

الأستاذة الدكتورة / شيرين فتحى شعير
أستاذ الأمراض العصبية
كلية الطب - جامعة القاهرة

الأستاذة الدكتورة / فاطمة محمد طه
أستاذ مساعد الكيمياء الحيوية
كلية الطب - جامعة القاهرة

الدكتور / عبد العظيم محمد رضا
مدرس الأمراض العصبية
كلية الطب – جامعة القاهرة

كلية الطب - جامعه القاهرة

Acknowledgement

Praise to ALLAH, Lord of Worlds, and may His blessing and peace be upon Mohamed, his servant and his messenger.

First of all, I am deeply thankful to GOD by the grace of whom this work was possible.

It's my pleasure to express my deepest gratitude and sincere thanks to **Prof. Dr. Shereen Fathi Sheir**, Professor of Neurology, Faculty of Medicine, Cairo University, for her generous concern, sincere supervision, valuable suggestions and cooperation, continuous advice and support, saving no effort or time in reading each word in this work, To her I will always grateful.

My deepest gratitude, Appreciations and thanks to **Dr. Fatma Mohamed Taha**, Assist professor of Biochemistry, Faculty of Medicine, Cairo University, for her sincere supervision, cooperation and continuous support throughout this work.

I wish also, to express my sincere gratitude and thanks to **Dr. Abdelazim Mohammed Reda**, Lecturer of Neurology, Faculty of Medicine, Cairo University, for his kind supervision, sincere encouragement, valuable advices and instructions throughout this work.

I would like to express my deep thanks and gratitude to **Prof. Dr. Aya Farouk**, professor of Neurophysiology, Faculty of Medicine, Cairo University, **Dr. Neveen ElFayoumy**, Assist professor of Neurophysiology, Faculty of Medicine, Cairo University **Dr. Marwa Shalaby**, Demonstrator of Neurophysiology, Faculty of Medicine, Cairo University, **Dr. Yosra Abdallah**, Resident of Neurophysiology, Faculty of Medicine, Cairo University for continuous guidance and valuable suggestions in this work.

I would like also to express my thanks and appreciation to my father **Prof. Dr. Mahmoud Ezzat** for his continuous encouragement and support, I ask god a happy and healthy life for him. And I wish to express my deepest appreciation to my mother and my brothers for the continuous support which make me indebted to them all my life.

Last but not, least I would like to express my gratitude to my colleagues in Neurology Department, Faculty of Medicine, Cairo University and everyone who helped me to complete this work.

Wael Mahmoud Ezzat

CONTENTS

List of abbreviations.....	i
List of tables.....	v
List of figures.....	vii
Abstract.....	x
Introduction.....	1
Aim of the work.....	4
Review of literature	
1- Chapter I: Pathophysiology and Etiology of Multiple Sclerosis.....	5
2- Chapter II: Diagnosis of multiple sclerosis	29
3- Chapter III: Role of Vitamin D & UVR therapy in Multiple Sclerosis.....	56
Patients and methods.....	92
Results.....	115
Discussion.....	160
Summary and conclusion.....	172
Recommendations.....	178
References.....	179
Appendices.....	
Arabic summary.....	

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS

1,25(OH)D	1,25-dihydroxy cholecalciferol
1-OHase	1 alpha -hydroxylase
25(OH)D	25 hydroxy cholecalciferol
ADAM	A disintegrin and metalloproteinase domain
AMP	Adenosine monophosphate
ANOVA	Analysis of variance
APCs	Antigen presenting cells
ATP	Adenosine triphosphate
AUA	American urological association
BBB	Blood-brain barrier
BDNF	Brain-derived neurotrophic factor
BMRC	British medical research council
CBC	Complete blood count
CCL	Chemokine C-motif ligand
CD	Clusters of differentiation
CH	Contact hypersensitivity
CLIA	Chemiluminiscent enzyme immunoassay
CMV	Cytomegalovirus
CNS	Central nervous system
CSF	Cerebrospinal fluid
CVS	Cardio-vascular stroke
CXCL	Chemokine (C-X-C Motif) ligand
DC	Dendritic cells
DNA	Deoxyribonucleic acid
DTH	Delayed type hypersensitivity
DW	Diffusion weighted

LIST OF ABBREVIATIONS

EAE	Experimental allergic encephalomyelitis
EBV	Epstein-barr virus
EDSS	Expanded disability status scale
ELISA	Enzyme-linked immunosorbent assay
Fas	Tumor necrosis factor receptor superfamily member 6
FLAIR	Fluid attenuated inversion recovery
GH	Growth hormone
GM	Gray matter
HC	Healthy control
HHV	Human herpes virus
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HRP	Horseradish peroxidase
ICAM-1	Intracellular adhesion molecule-1
ICARS	International cooperative ataxia rating scale
IFN	Interferon
IGF	Insulin-like growth factor
Igs	Immunoglobulins
IL	Interleukin
IM	Immunomodulatory
iNOS	Inducible nitric oxide synthase
IU	International units
JNK	c-Jun N-terminal kinase
LFA-1	Leukocyte functional antigen
LL	Lower limb
MAP kinase	Mitogen-activated protein kinase
MAS	Modified ashworth scale
MBP	Myelin basic protein
MCP	Monocyte chemotactic protein
MED	Minimum erythema dose

LIST OF ABBREVIATIONS

MHC	Major histocompatibility complex
MICARS	Modified international cooperative ataxia rating scale
MMF	Mycophenolate mofetil
MMPs	Matrix metalloproteinases
MMSE	Mini mental state examination
MO	Monocyte
MP	Methyl prednisolone
MRC	Medical research council
MRI	Magnetic resonance imaging
MRS	Magnetic resonance spectroscopy
MS	Multiple sclerosis
MSH	Melanocyte stimulating hormone
NG2	Neural glia antigen 2
NGM	Normal grey matter
NKT	Natural killer T cell
NMO	Neuromyelitis optica
NO	Nitric oxide
OCB	Oligoclonal band
OCT	Optical coherence tomography
O.D	Optical densit
OPC	Oligodendrocyte precursor cells
PET	Positron emission tomography
PMN	Polymorphnuclear neutrophils
PPMS	Primary progressive multiple sclerosis
PTH	Parathyroid hormone
PTHrP	PTH related peptide
QoL	Quality of life
RANK	Receptor activator nuclear factor-Kb
RANKL	Receptor activator nuclear factor-Kb ligand
RANTES	Regulated upon activation, normal T-cell expressed, and

LIST OF ABBREVIATIONS

	secreted
RNA	Ribonucleic acid
ROI	Regions of interest
ROM	Range of motion
RORγ	Retinoid-related orphan receptor gamma
ROS	Reactive oxygen species
RRMS	Relapsing remitting multiple sclerosis
SD	Standard deviation
SDMT	Symbol digit modalities test
SHPT	Secondary hyperparathyroidism
SPECT	Single photon emission computerized tomography
SPMS	Secondary progressive multiple sclerosis
SPSS	Statistical package version 12
TGF-β	Transforming growth factor beta
Th1	T helper 1
Th2	T helper 2
TLR	Toll-like receptors
TNF-α	Tumor necrosis factor- α
TRAF-6	Tumor necrosis factor receptor associated factor-6
TRAIL	Tumor necrosis factor related apoptosis inducing ligand
Treg	Regulatory T cell (suppressor T cell)
TYK2	Tyrosine kinase 2
UCA	Urocanic acid
UL	Upper limb
UVR	Ultraviolet radiation
VCAM-1	Vascular cell adhesion molecule
VDR	Vitamin D receptors
VEP	Visual evoked potential
VLA-4	Very Late antigen-4
WHO	World health organization

List of tables

Table (1)	Mechanisms of demyelination in multiple sclerosis.....	12
Table (2)	Histopathological patterns in MS	15
Table (3)	Risk of developing multiple sclerosis according to the relationship to a multiple sclerosis patient.....	30
Table (4)	Prognostic factors in multiple sclerosis.....	48
Table (5)	The Mean age of patients in group I and II	116
Table (6)	The sex distribution of patients in group I and II.	116
Table (7)	The mean duration of illness of patients in group I and II.....	118
Table (8)	The mean number of attacks of patients in group I and II.....	118
Table (9)	Comparison of different clinical examination among group I pre and post UVR therapy patients	120
Table (10)	The median scores of different clinical scales in group I pre and post UVR therapy patients.....	122
Table (11)	The mean number of MRI lesions in pre and post UVR therapy patients.....	123
Table (12)	The mean values of VEP (amplitude & latency) and H-reflex (latency & H/M ratio) among group I pre and post UVR therapy patients.....	127
Table (13)	Means of serum 25(OH)cholecalciferol among group I pre, post 1m & post 3m UVR therapy patients.....	130
Table (14)	The results of clinical examination among group II and group I (post) UVR therapy patients.....	132
Table (15)	The median scores of different clinical scales in group II and group I (post) UVR therapy patients.....	134

Table (16)	The mean number of MRI lesions between group II and group I (post) UVR therapy patients.....	136
Table (17)	The mean value of VEP (amplitude & latency) and H-reflex between Group II and Group I (post) UVR therapy patients.....	139
Table (18)	The serum 25(OH)cholecalciferol between group II and group I post(1m & 3m) UVR therapy patients.	143
Table (19)	The mean number of new attacks among group II and group I (post) UVR therapy patients.....	144
Table (20)	The mean serum 25 hydroxy-cholecalciferol between group I and group II patients.....	146
Table (21)	The serum 25 hydroxy-cholecalciferol between male & female patients.....	150
Table (22)	Comparing the mean value between Diff-D1 and Diff-D2.....	151
Table (23)	Showing correlation between Diff-D1 and Diff-D2 using Spearman's rho method.....	151
Table (24)	P-value of Diff-D1 and Diff-D2 across males and females.....	152
Table (25)	Showing correlation between Diff-D1 and Diff-D2 with different rating scales (post) using Spearman's rho method	153
Table (26)	Showing correlation between Diff-D1 and Diff-D2 with different neurophysiological studies using Spearman's rho method.....	154
Table (27)	Showing correlation between Diff-D1 and Diff-D2 with number of new attacks using Spearman's rho method.....	155
Table (28)	Showing correlation of Diff-D1 between all neurophysiological studies with all rating scales using Spearman's rho method.....	156
Table (29)	Showing correlation of Diff-D2 between all neurophysiological studies with all rating scales using Spearman's rho method.....	158

List of figures

Fig. (1)	Various factors influencing the onset of MS.....	9
Fig. (2)	The role of immune system in MS pathogenesis.....	20
Fig. (3)	Cellular contributions to MS.....	21
Fig. (4)	Schematic diagram of the mitochondrial respiratory chain located in the inner mitochondrial membrane.....	23
Fig. (5)	Flow chart showing the stages in the diagnosis of multiple sclerosis (MS) leading to a confirmed diagnosis.....	42
Fig. (6)	RR MS with partial recovery	43
Fig. (7)	RRMS with complete recovery	44
Fig. (8)	PP MS without Plateaus	45
Fig. (9)	PP MS with temporary improvement.....	45
Fig.(10)	Secondary progressive (SP).....	46
Fig.(11)	Progressive-relapsing (PR) MS	47
Fig.(12)	Sources and metabolism of vitamin D	58
Fig.(13)	Determinants of low or impaired vitamin D status and hypothesized intermediary mechanisms underlying increased risk and severity of multiple sclerosis.....	67
Fig.(14)	Effect of vitamin D on immune cells	71
Fig.(15)	Schematic diagram of the relation between UVR exposure and burden of the disease.....	76
Fig.(16)	Proposed mechanisms of systemic immunosuppression following UV irradiation of skin.....	82
Fig.(17)	Light-stimuli-mediated hypothesis.....	85
Fig.(18)	Mean serum 25-hydroxyvitamin D concentrations in different populations	89

Fig.(19)	Showing anatomical localization of H-reflex.....	102
Fig.(20)	Sex distribution in study groups.....	117
Fig.(21)	Percentage of affected cases between pre & post UVR therapy across different clinical data.....	121
Fig.(22)	Mean value between pre & post UVR therapy patients in different rating scales	122
Fig.(23)	MRI results of pre & post UVR therapy patients in group I.....	124
Fig.(24)	VEP trace of Rt & Lt eye amplitude & latency.....	125
Fig.(25)	H-reflex trace of LL amplitude & latency.....	126
Fig.(26)	Mean values of VEP between pre & post UVR therapy patients.....	128
Fig.(27)	Mean values of H-reflex between pre & post UVR therapy patients.....	129
Fig.(28)	Mean serum Vit D level in group I pre, post 1m & post 3m UVR therapy patients.....	131
Fig.(29)	percentage of clinically +ve cases among group I & II.....	133
Fig.(30)	Mean value between group II & group I(post) UVR therapy patients in different rating scales.....	135
Fig.(31)	MRI results among group I (post) & II.....	136
Fig.(32)	VEP trace of Rt & Lt eye amplitude & latency.....	137
Fig.(33)	H-reflex trace of UL amplitude & latency.....	138
Fig.(34)	Mean values of VEP between group II & group I (post) UVR therapy patients.....	141

Fig.(35)	Mean value of H-reflex between group II & group I (post) UVR therapy patients.....	142
Fig.(36)	percentage of patients developed new attacks among group I & II.....	144
Fig.(37)	Serum Vitamin D level in group I & group II.....	147
Fig.(38)	Serum Vitamin D level in group I (post 3m) & group II.....	148
Fig.(39)	Serum Vitamin D level in male & female patients.....	150

Abstract

Multiple sclerosis (MS) is a devastating neurological disease that attacks young adults and affects all aspects of their lives. vitamin D deficiency is common in MS patient and may play a role in its pathogenesis. Recent studies suggest ultraviolet radiation (UVR)/vitamin D is protective against the development of multiple sclerosis (MS). Ultraviolet radiation (UVR) influences the immune system.

Key Words:

- Multiple sclerosis
- Vitamin D
- Ultraviolet radiation